Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Gianfranco Ferraccioli; Josef S. Smolen; Monika M. Schoels; Norihiro Nishimoto; Ferdinand C. Breedveld; Gerd R. Burmester; Maxime Dougados; Paul Emery; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K. Kvien; Miho Murakami; Neil Betteridge; Clifton O. Bingham Iii; Vivian Bykerk; Ernest H. Choy; Bernard Combe; Maurizio Cutolo; Winfried Graninger; Angel Lanas; Emilio Martin-Mola; Carlomaurizio Montecucco; Mikkel Ostergaard; Karel Pavelka; Andrea Rubbert-Roth; Naveed Sattar; Marieke Scholte-Voshaar; Yoshiya Tanaka; Michael Trauner; Gabriele Valentini; Kevin L. Winthrop; Maarten De Wit; Désirée Van Der Heijde

doi:10.1136/annrheumdis-2012-202469

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Gianfranco Ferraccioli, Josef S. Smolen, Monika M. Schoels, Norihiro Nishimoto, Ferdinand C. Breedveld, Gerd R. Burmester, Maxime Dougados, Paul Emery, Cem Gabay, Allan Gibofsky, Juan Jesus Gomez-Reino, Graeme Jones, Tore K. Kvien, Miho Murakami, Neil Betteridge, Clifton O. Bingham Iii, Vivian Bykerk, Ernest H. Choy, Bernard Combe, Maurizio CutoloWinfried Graninger, Angel Lanas, Emilio Martin-Mola, Carlomaurizio Montecucco, Mikkel Ostergaard, Karel Pavelka, Andrea Rubbert-Roth, Naveed Sattar, Marieke Scholte-Voshaar, Yoshiya Tanaka, Michael Trauner, Gabriele Valentini, Kevin L. Winthrop, Maarten De Wit, Désirée Van Der Heijde

Risultato della ricerca: Contributo in rivista › Articolo in rivista

88 Citazioni (Scopus)

Abstract

Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.

Lingua originale	English
pagine (da-a)	482-492
Numero di pagine	11
Rivista	EARD
Volume	72
DOI	https://doi.org/10.1136/annrheumdis-2012-202469
Stato di pubblicazione	Pubblicato - 2013
Pubblicato esternamente	Sì

Keywords

interleukin-6
rheumatoid arthritis

Accesso al documento

10.1136/annrheumdis-2012-202469

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Ferraccioli, G., Smolen, J. S., Schoels, M. M., Nishimoto, N., Breedveld, F. C., Burmester, G. R., Dougados, M., Emery, P., Gabay, C., Gibofsky, A., Gomez-Reino, J. J., Jones, G., Kvien, T. K., Murakami, M., Betteridge, N., Bingham Iii, C. O., Bykerk, V., Choy, E. H., Combe, B., ... Van Der Heijde, D. (2013). Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. EARD, 72, 482-492. https://doi.org/10.1136/annrheumdis-2012-202469

@article{6a58cacc986b4fcb9dc603d4b4a1b0f4,

title = "Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions",

abstract = "Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.",

keywords = "interleukin-6, rheumatoid arthritis, interleukin-6, rheumatoid arthritis",

author = "Gianfranco Ferraccioli and Smolen, {Josef S.} and Schoels, {Monika M.} and Norihiro Nishimoto and Breedveld, {Ferdinand C.} and Burmester, {Gerd R.} and Maxime Dougados and Paul Emery and Cem Gabay and Allan Gibofsky and Gomez-Reino, {Juan Jesus} and Graeme Jones and Kvien, {Tore K.} and Miho Murakami and Neil Betteridge and {Bingham Iii}, {Clifton O.} and Vivian Bykerk and Choy, {Ernest H.} and Bernard Combe and Maurizio Cutolo and Winfried Graninger and Angel Lanas and Emilio Martin-Mola and Carlomaurizio Montecucco and Mikkel Ostergaard and Karel Pavelka and Andrea Rubbert-Roth and Naveed Sattar and Marieke Scholte-Voshaar and Yoshiya Tanaka and Michael Trauner and Gabriele Valentini and Winthrop, {Kevin L.} and {De Wit}, Maarten and {Van Der Heijde}, D{\'e}sir{\'e}e",

year = "2013",

doi = "10.1136/annrheumdis-2012-202469",

language = "English",

volume = "72",

pages = "482--492",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "London: BMJ Publishing.",

}

Ferraccioli, G, Smolen, JS, Schoels, MM, Nishimoto, N, Breedveld, FC, Burmester, GR, Dougados, M, Emery, P, Gabay, C, Gibofsky, A, Gomez-Reino, JJ, Jones, G, Kvien, TK, Murakami, M, Betteridge, N, Bingham Iii, CO, Bykerk, V, Choy, EH, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin-Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert-Roth, A, Sattar, N, Scholte-Voshaar, M, Tanaka, Y, Trauner, M, Valentini, G, Winthrop, KL, De Wit, M & Van Der Heijde, D 2013, 'Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions', EARD, vol. 72, pagg. 482-492. https://doi.org/10.1136/annrheumdis-2012-202469

TY - JOUR

T1 - Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

AU - Ferraccioli, Gianfranco

AU - Smolen, Josef S.

AU - Schoels, Monika M.

AU - Nishimoto, Norihiro

AU - Breedveld, Ferdinand C.

AU - Burmester, Gerd R.

AU - Dougados, Maxime

AU - Emery, Paul

AU - Gabay, Cem

AU - Gibofsky, Allan

AU - Gomez-Reino, Juan Jesus

AU - Jones, Graeme

AU - Kvien, Tore K.

AU - Murakami, Miho

AU - Betteridge, Neil

AU - Bingham Iii, Clifton O.

AU - Bykerk, Vivian

AU - Choy, Ernest H.

AU - Combe, Bernard

AU - Cutolo, Maurizio

AU - Graninger, Winfried

AU - Lanas, Angel

AU - Martin-Mola, Emilio

AU - Montecucco, Carlomaurizio

AU - Ostergaard, Mikkel

AU - Pavelka, Karel

AU - Rubbert-Roth, Andrea

AU - Sattar, Naveed

AU - Scholte-Voshaar, Marieke

AU - Tanaka, Yoshiya

AU - Trauner, Michael

AU - Valentini, Gabriele

AU - Winthrop, Kevin L.

AU - De Wit, Maarten

AU - Van Der Heijde, Désirée

PY - 2013

Y1 - 2013

N2 - Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.

AB - Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.

KW - interleukin-6

KW - rheumatoid arthritis

KW - interleukin-6

KW - rheumatoid arthritis

UR - http://hdl.handle.net/10807/41188

U2 - 10.1136/annrheumdis-2012-202469

DO - 10.1136/annrheumdis-2012-202469

M3 - Article

VL - 72

SP - 482

EP - 492

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo